Cargando…

High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients

BACKGROUND: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain...

Descripción completa

Detalles Bibliográficos
Autores principales: Sejdic, Adin, Frische, Anders, Jørgensen, Charlotte Sværke, Rasmussen, Lasse Dam, Trebbien, Ramona, Dungu, Arnold, Holler, Jon G., Ostrowski, Sisse Rye, Eriksson, Robert, Søborg, Christian, Nielsen, Thyge L., Fischer, Thea K., Lindegaard, Birgitte, Franck, Kristina Træholt, Harboe, Zitta Barrella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875770/
https://www.ncbi.nlm.nih.gov/pubmed/36698135
http://dx.doi.org/10.1186/s12985-023-01974-8
_version_ 1784878027484692480
author Sejdic, Adin
Frische, Anders
Jørgensen, Charlotte Sværke
Rasmussen, Lasse Dam
Trebbien, Ramona
Dungu, Arnold
Holler, Jon G.
Ostrowski, Sisse Rye
Eriksson, Robert
Søborg, Christian
Nielsen, Thyge L.
Fischer, Thea K.
Lindegaard, Birgitte
Franck, Kristina Træholt
Harboe, Zitta Barrella
author_facet Sejdic, Adin
Frische, Anders
Jørgensen, Charlotte Sværke
Rasmussen, Lasse Dam
Trebbien, Ramona
Dungu, Arnold
Holler, Jon G.
Ostrowski, Sisse Rye
Eriksson, Robert
Søborg, Christian
Nielsen, Thyge L.
Fischer, Thea K.
Lindegaard, Birgitte
Franck, Kristina Træholt
Harboe, Zitta Barrella
author_sort Sejdic, Adin
collection PubMed
description BACKGROUND: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity, infectious viral shedding and NAb titers as well as the association between NAb titers and disease severity in hospitalized COVID-19 patients in Denmark 2020–2021. MATERIALS AND METHODS: Prospective single-center observational cohort study of 47 hospitalized COVID-19 patients. Oropharyngeal swabs were collected at eight time points during the initial 30 days of inclusion. Serum samples were collected after a median time of 7 (IQR 5 – 10), 37 (IQR 35 – 38), 97 (IQR 95 – 100), and 187 (IQR 185 – 190) days after symptom onset. NAb titers were determined by an in-house live virus microneutralization assay. Viral culturing was performed in Vero E6 cells. RESULTS: Patients with high disease severity had higher mean log(2) NAb titers at day 37 (1.58, 95% CI [0.34 –2.81]), 97 (2.07, 95% CI [0.53–3.62]) and 187 (2.49, 95% CI [0.20– 4.78]) after symptom onset, compared to patients with low disease severity. Peak viral load (0.072, 95% CI [− 0.627 – 0.728]), expressed as log(10) SARS-CoV-2 copies/ml, was not associated with disease severity. Virus cultivation attempts were unsuccessful in almost all (60/61) oropharyngeal samples collected shortly after hospital admission. CONCLUSIONS: We document an association between high disease severity and high mean NAb titers at days 37, 97 and 187 after symptom onset. However, peak viral load during admission was not associated with disease severity. Trial registration. The study is registered at https://clinicaltrials.gov/ (NCT05274373). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-01974-8.
format Online
Article
Text
id pubmed-9875770
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98757702023-01-25 High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients Sejdic, Adin Frische, Anders Jørgensen, Charlotte Sværke Rasmussen, Lasse Dam Trebbien, Ramona Dungu, Arnold Holler, Jon G. Ostrowski, Sisse Rye Eriksson, Robert Søborg, Christian Nielsen, Thyge L. Fischer, Thea K. Lindegaard, Birgitte Franck, Kristina Træholt Harboe, Zitta Barrella Virol J Research BACKGROUND: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity, infectious viral shedding and NAb titers as well as the association between NAb titers and disease severity in hospitalized COVID-19 patients in Denmark 2020–2021. MATERIALS AND METHODS: Prospective single-center observational cohort study of 47 hospitalized COVID-19 patients. Oropharyngeal swabs were collected at eight time points during the initial 30 days of inclusion. Serum samples were collected after a median time of 7 (IQR 5 – 10), 37 (IQR 35 – 38), 97 (IQR 95 – 100), and 187 (IQR 185 – 190) days after symptom onset. NAb titers were determined by an in-house live virus microneutralization assay. Viral culturing was performed in Vero E6 cells. RESULTS: Patients with high disease severity had higher mean log(2) NAb titers at day 37 (1.58, 95% CI [0.34 –2.81]), 97 (2.07, 95% CI [0.53–3.62]) and 187 (2.49, 95% CI [0.20– 4.78]) after symptom onset, compared to patients with low disease severity. Peak viral load (0.072, 95% CI [− 0.627 – 0.728]), expressed as log(10) SARS-CoV-2 copies/ml, was not associated with disease severity. Virus cultivation attempts were unsuccessful in almost all (60/61) oropharyngeal samples collected shortly after hospital admission. CONCLUSIONS: We document an association between high disease severity and high mean NAb titers at days 37, 97 and 187 after symptom onset. However, peak viral load during admission was not associated with disease severity. Trial registration. The study is registered at https://clinicaltrials.gov/ (NCT05274373). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-01974-8. BioMed Central 2023-01-25 /pmc/articles/PMC9875770/ /pubmed/36698135 http://dx.doi.org/10.1186/s12985-023-01974-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sejdic, Adin
Frische, Anders
Jørgensen, Charlotte Sværke
Rasmussen, Lasse Dam
Trebbien, Ramona
Dungu, Arnold
Holler, Jon G.
Ostrowski, Sisse Rye
Eriksson, Robert
Søborg, Christian
Nielsen, Thyge L.
Fischer, Thea K.
Lindegaard, Birgitte
Franck, Kristina Træholt
Harboe, Zitta Barrella
High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients
title High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients
title_full High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients
title_fullStr High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients
title_full_unstemmed High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients
title_short High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients
title_sort high titers of neutralizing sars-cov-2 antibodies six months after symptom onset are associated with increased severity in covid-19 hospitalized patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875770/
https://www.ncbi.nlm.nih.gov/pubmed/36698135
http://dx.doi.org/10.1186/s12985-023-01974-8
work_keys_str_mv AT sejdicadin hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT frischeanders hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT jørgensencharlottesværke hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT rasmussenlassedam hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT trebbienramona hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT dunguarnold hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT hollerjong hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT ostrowskisisserye hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT erikssonrobert hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT søborgchristian hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT nielsenthygel hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT fischertheak hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT lindegaardbirgitte hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT franckkristinatræholt hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients
AT harboezittabarrella hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients